Print this page
March 02, 2018

Participants need for the Flu Vaccine Study

The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant. This study is open to healthy adults ages 19-64 who have not already received the 2017-2018 flu vaccine. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into. Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period. For more information or to see if you qualify for this study, please contact us at 205-934-6777 or 205-996-4099